JP6545177B2 - 抗菌薬としてのアリール置換アミノメチルスペクチノマイシン類似体 - Google Patents

抗菌薬としてのアリール置換アミノメチルスペクチノマイシン類似体 Download PDF

Info

Publication number
JP6545177B2
JP6545177B2 JP2016545270A JP2016545270A JP6545177B2 JP 6545177 B2 JP6545177 B2 JP 6545177B2 JP 2016545270 A JP2016545270 A JP 2016545270A JP 2016545270 A JP2016545270 A JP 2016545270A JP 6545177 B2 JP6545177 B2 JP 6545177B2
Authority
JP
Japan
Prior art keywords
och
nhch
chf
chcl
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016545270A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535075A5 (enExample
JP2016535075A (ja
Inventor
リー，リチャード，イー．
ワイジャラクチ，サマンシー，エル．
ブルーン，デビッド，エフ．
リウ，ジウユ
ツェン，ツォン
ロッシュ，ジェーソン，ダブリュ．
Original Assignee
セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド
セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド, セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド filed Critical セント ジュード チルドレンズ リサーチ ホスピタル インコーポレイテッド
Publication of JP2016535075A publication Critical patent/JP2016535075A/ja
Publication of JP2016535075A5 publication Critical patent/JP2016535075A5/ja
Application granted granted Critical
Publication of JP6545177B2 publication Critical patent/JP6545177B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Fodder In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2016545270A 2013-09-29 2014-09-29 抗菌薬としてのアリール置換アミノメチルスペクチノマイシン類似体 Expired - Fee Related JP6545177B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361884085P 2013-09-29 2013-09-29
US61/884,085 2013-09-29
PCT/US2014/058137 WO2015048692A1 (en) 2013-09-29 2014-09-29 Aryl substituted aminomethyl spectinomycin analogs as antibacterial agents

Publications (3)

Publication Number Publication Date
JP2016535075A JP2016535075A (ja) 2016-11-10
JP2016535075A5 JP2016535075A5 (enExample) 2017-11-09
JP6545177B2 true JP6545177B2 (ja) 2019-07-17

Family

ID=52744583

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016545270A Expired - Fee Related JP6545177B2 (ja) 2013-09-29 2014-09-29 抗菌薬としてのアリール置換アミノメチルスペクチノマイシン類似体

Country Status (6)

Country Link
US (1) US10266544B2 (enExample)
EP (1) EP3049154B1 (enExample)
JP (1) JP6545177B2 (enExample)
AU (1) AU2014324535B2 (enExample)
CA (1) CA2924733C (enExample)
WO (1) WO2015048692A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180141897A1 (en) 2014-12-08 2018-05-24 The Research Foundation For The State University Of New York Anti-fungals targeting the synthesis of fungal shingolipids
EP3638649A4 (en) 2017-06-16 2021-03-17 The Research Foundation for The State University of New York FUNGUSKID AGENTS AGAINST THE SYNTHESIS OF FUNGAL SHINGOLIPIDS
US20210388012A1 (en) * 2018-11-05 2021-12-16 St. Jude Children's Research Hospital, Inc. Methods and compositions for prodrug forms of spectinomycin and spectinamide analogs
CN111239265B (zh) * 2018-11-28 2022-07-26 江苏先声药业有限公司 一种测定阿莫西林克拉维酸钾药物组合物中克拉维酸有关物质的液相色谱方法
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3207764A (en) * 1962-01-22 1965-09-21 Upjohn Co Actinospectacin acylates
DE2756914A1 (de) 1977-12-21 1979-07-05 Thomae Gmbh Dr K 4-spectinomycylamin und seine physiologisch vertraegliche salze, verfahren zur herstellung und diese stoffe enthaltende arzneimittel
US4465848A (en) 1981-10-23 1984-08-14 The Upjohn Company Spectinomycin compounds
EP0079125B1 (en) * 1981-10-23 1989-04-05 The Upjohn Company 3-substituted spectinomycin analogues and their preparation
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
EP1278542A2 (en) 2000-05-05 2003-01-29 Cytos Biotechnology AG Molecular antigen arrays and vaccines
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
CN101675993A (zh) 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
WO2005101466A2 (en) 2003-12-19 2005-10-27 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
US20090226525A1 (en) 2007-04-09 2009-09-10 Chimeros Inc. Self-assembling nanoparticle drug delivery system
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
WO2009106999A2 (en) 2008-02-28 2009-09-03 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Hollow nanoparticles and uses thereof
WO2010047839A1 (en) 2008-10-25 2010-04-29 Aura Biosciences Modified plant virus particles and uses therefor
CA2768582C (en) * 2009-07-24 2017-02-14 University Of Tennessee Research Foundation Spectinamides as anti-tuberculosis agents
CN101671336B (zh) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途

Also Published As

Publication number Publication date
WO2015048692A1 (en) 2015-04-02
EP3049154A1 (en) 2016-08-03
EP3049154B1 (en) 2019-11-13
CA2924733A1 (en) 2015-04-02
AU2014324535A1 (en) 2016-04-07
EP3049154A4 (en) 2017-03-01
US10266544B2 (en) 2019-04-23
AU2014324535B2 (en) 2017-03-30
CA2924733C (en) 2018-02-27
US20160347762A1 (en) 2016-12-01
JP2016535075A (ja) 2016-11-10

Similar Documents

Publication Publication Date Title
US11866419B2 (en) Antibacterial compounds
KR101118402B1 (ko) 5-하이드록시메틸-옥사졸리딘-2-원 유도체
EP3049154B1 (en) Aryl substituted aminomethyl spectinomycin analogs as antibacterial agents
JP2022513851A (ja) 抗菌剤としてのイミダゾピラジン誘導体
CN112204037A (zh) 用于治疗和预防细菌感染的新氧代喹嗪化合物
CN102471283A (zh) 黄素衍生物
TW201731844A (zh) 羥基烷基噻二唑衍生物
EP3506922A1 (en) Substituted urea depsipeptide analogs as activators of the clpp endopeptidase
EP3887370B1 (en) Tricyclic compounds for the treatment and prophylaxis of bacterial infection
WO2016123146A1 (en) Bridged compounds for the treatment of bacterial infections
JP2024540590A (ja) Ｂｃｌ－２阻害剤としての化合物
CA3012567A1 (en) Antibacterial compounds
WO2017046606A1 (en) Antibacterial compounds
WO2016024096A1 (en) Antibacterial compounds
TW201309689A (zh) 含胺基之吡咯啶酮衍生物
WO2025049804A2 (en) Agents for the treatment of non-replicating bacteria
WO2024050062A1 (en) Aminopiperazines with broad spectrum antimicrobial activity
HK40096422A (en) Novel heteroaryl-substituted imidazole derivatives
JPWO2005073238A1 (ja) ピリドベンズオキサジン誘導体
TW202116782A (zh) 喹啉酮衍生物
TW201840322A (zh) 羥烷基噻二唑衍生物之ｎ－膦醯基氧基甲基前驅藥
HK1254677B (en) Antibacterial compounds
WO2020127624A1 (en) Oxopyrido[1,2-a]pyrimidine compounds for the treatment and prophylaxis of bacterial infection
WO2016189304A1 (en) Antibacterial compounds
WO2020097065A1 (en) Methods and compositions for prodrug forms of spectinomycin and spectinamide analogs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170927

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190618

R150 Certificate of patent or registration of utility model

Ref document number: 6545177

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees